Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes

American Journal of Health-System Pharmacy

Volumn 72, Issue 5, 2015, Pages 361-372

  Vivian, Eva M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE PLUS SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BACKACHE; BALANITIS; CANCER RISK; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG SAFETY; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHINOPHARYNGITIS; URINARY EXCRETION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINITIS; VULVOVAGINAL DISEASE; VULVOVAGINITIS; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2;

BENZHYDRYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84946720305     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140168     Document Type: Article

References (79)

1. Mugavero MJ, May M, Harris R et al. Does short-term virologic failure translate to clinical events in antiretroviralnaive patients initiating antiretroviral therapy in clinical practice? AIDS. 2008; 22:2481-92.
2. Centers for Disease Control and Prevention. National diabetes statistics report, 2014: estimates of diabetes and its burden in the United States. www.cdc.gov/diabetes/pubs/statsreport14/nationaldiabetes-report-web.pdf (accessed 2014 Jul 2).
3. Centers for Disease Control and Prevention. US obesity trends. www.cdc.gov/obesity/data/trends.html (accessed 2014 Jun 10).
4. Boyle JP, Thompson TJ, Gregg EW et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010; 8:29.
5. Singleton JR, Smith AG, Russell JW et al. Microvascular complications of impaired glucose tolerance. Diabetes. 2003; 52:2867-73.
6. Fox CS, Coady S, Sorlie PD et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framing ham Heart Study. Circulation. 2007; 115:1544-50.
7. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37(suppl 1):S14-80.
8. Garber AJ, Abrahamson MJ, Barzilay JI et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement-executive summary. Endocr Pract. 2013; 19:536-57.
9. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203.
10. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369:145-54.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.
13. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17.
14. Stark Casagrande S, Fradkin JE, Saydah SH et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013; 36:2271-9.
15. Pfister M, Whaley JM, Zhang L et al. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. Clin Pharmacol Ther. 2011; 89:621-5.
16. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011; 120(Mar):S1-6.
17. Bakris GL, Fonseca VA, Sharma K et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009; 75:1272-7.
18. Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011; 22:104-12.
19. Kanai Y, Lee WS, You G et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994; 93:397-404.
20. Chen J, Williams S, Ho S et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010; 1:57-92.
21. Lee WS, Kanai Y, Wells RG et al. The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem. 1994; 269:12032-9.
22. Chin E, Zhou J, Bondy C. Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. J Clin Invest. 1993; 91:1810-5.
23. Ferrannini E. Learning from glycosuria. Diabetes. 2011; 60:695-6.
24. DeFronzo RA, Hompesch M, Kasichayanula S et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013; 36:3169-76.
25. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010; 27:136-42.
26. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009; 32(suppl 2):S151-6.
27. Whaley JM, Tirmenstein M, Reilly TP et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2012; 5:135-48.
28. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9:551-9.
29. Ehrenkranz JR, Lewis NG, Kahn CR et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 21:31-8.
30. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013; 1:140-51.
31. Fujimori Y, Katsuno K, Nakashima I et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008; 327:268-76.
32. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008; 57:1723-9.
33. Katsuno K, Fujimori Y, Takemura Y et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007; 320:323-30.
34. Macdonald FR, Peel JE, Jones HB et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010; 12:1004-12.
35. Rosenstock J, Seman LJ, Jelaska A et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013; 15:1154-60.
36. Wilding JP, Ferrannini E, Fonseca VA et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013; 15:403-9.
37. Miao Z, Nucci G, Amin N et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013; 41:445-56.
38. Seino Y, Sasaki T, Fukatsu A et al. Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. Diabetes. 2012; 61(suppl 1):A266. Abstract.
39. Kadowaki T, Ikeda S, Takano Y et al. Tofogliflozin, a novel and selective SGLT2 inhibitor, improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and excercise alone. Diabetes. 2012; 61(suppl 1):A22. Abstract.
40. Zambrowicz B, Freiman J, Brown PM et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012; 92:158-69.
41. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009; 85:520-6.
42. Obermeier M, Yao M, Khanna A et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010; 38:405-14.
43. Kasichayanula S, Liu X, Zhang W et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes Metab. 2011; 13:770-3.
44. Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009; 85:513-9.
45. Kasichayanula S, Liu X, Shyu WC et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodiumglucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011; 13:47-54.
46. Kasichayanula S, Chang M, Liu X et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012; 29:163-77.
47. Kohan DE, Fioretto P, Tang W et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014; 85:962-71.
48. List JF, Woo V, Morales E et al. Sodiumglucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32:650-7.
49. Wilding JP, Norwood P, T'Joen C et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009; 32:1656-62.
50. Ferrannini E, Ramos SJ, Salsali A et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, Phase 3 trial. Diabetes Care. 2010; 33:2217-24.
51. Woo V, Tang W, Salsali A et al. Long-term efficacy of dapagliflozin monotherapy in patients with type 2 diabetes mellitus. Paper presented at World Diabetes Congress. Dubai, United Arab Emirates; 2011 Dec 4-8.
52. Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375:2223-33.
53. Bailey CJ, Gross JL, Hennicken D et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, doubleblind, placebo-controlled 102-week trial. BMC Med. 2013; 11:43.
54. Henry RR, Murray AV, Marmolejo MH et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66:446-56.
55. Strojek K, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebocontrolled trial. Diabetes Obes Metab. 2011; 13:928-38.
56. Rosenstock J, Vico M, Wei L et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012; 35:1473-8.
57. Jabbour SA, Hardy E, Sugg J et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014; 37:740-50.
58. Hamaty M. Insulin treatment for type 2 diabetes: when to start, which to use. Cleve Clin J Med. 2011; 78:332-42.
59. Wilding JP, Woo V, Soler NG et al. Longterm efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med. 2012; 156:405-15.
60. Wilding JP, Woo V, Rohwedder K et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over two years. Diabetes Obes Metab. 2014; 16:124-36.
61. Nauck MA, del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34:2015-22.
62. Nauck M, del Prato S, Rohwedder K et al. Long-term efficacy and safety of addon dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results. Diabetes. 2011; 60(suppl 1):0040-LB. Abstract.
63. Leiter LA, Cefalu WT, de Bruin TW et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014; 61:1252-62.
64. Cefalu WT, Leiter LA, de Bruin TW et al. Dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension. Diabetes. 2012; 61(suppl 1):A271. Abstract.
65. Kasichayanula S, Liu X, Pe Benito M et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013; 76:432-44.
66. Ptaszynska A, Chalamandaris A, Sugg JE et al. Effect of dapagliflozin on renal function. Diabetes. 2012; 61(suppl 1):A283. Abstract.
67. Ljunggren O, Bolinder J, Johansson L et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012; 14:990-9.
68. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359:1811-21.
69. Kodama S, Saito K, Yachi Y et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009; 32:1737-42.
70. Lambers Heerspink HJ, de Zeeuw D, Wie L et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15:853-62.
71. Food and Drug Administration. FDA briefing document: dapagliflozin (December 12, 2013). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378076.pdf (accessed 2014 Jun 5).
72. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003; 26:510-3.
73. Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents. 2003; 22:s35-43.
74. Muller LM, Gorter KJ, Hak E et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005; 41:281-8.
75. Johnsson KM, Ptaszynska A, Schmitz B et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013; 27:479-84.
76. Johnsson KM, Ptaszynska A, Schmitz B et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013; 27:473-8.
77. Endocrinologic and Metabolic Drugs Advisory Committee, Food and Drug Administration. Background document, dapagliflozin (December 12, 2013). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378079.pdf (accessed 2014 Jun 5).
78. Griffiths TR, on behalf of Action on Bladder Cancer. Current perspectives in bladder cancer management. Int J Clin Pract. 2013; 67:435-48.
79. ClinicalTrials .gov. Mul t icenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). http://clinicaltrials.gov/ct2/show/NCT01730534?term=declare&rank=2 (accessed 2014 Jun 5).